RVL Pharmaceuticals plc Reports First Quarter 2023 Financial Results; Provides Commercial Update
2022 includes $15,500 in licensing revenue recognized in connection with an amendment of our License Agreement with Santen, effective March 31, 2022, net of a $500 transaction fee expense classified... | May 11, 2023
Source: marketscreener.com